January 19, 2021
Article
January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.
December 28, 2020
Article
Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.
December 03, 2020
Video
Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.
December 02, 2020
Video
John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.
November 25, 2020
Video
Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.
November 19, 2020
Article
Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.